A Motivation-enhancing App to Retain Patients With Hay Fever in a Trial After Treatment
Status
Conditions
Treatments
Details and patient eligibility
About
The motivation-enhancing intervention is designed for participants in the ILIT.NU trial. The participants are patients with hay fever who are treated with a vaccination in an inguinal lymph node. The motivation-enhancing intervention is a web-based app developed in collaboration with patient partners and is intended to increase retention and reporting in the ILIT.NU trial.
Full description
The ILIT.NU trial (EudraCT 2020-001060-28) investigates whether patient reported outcome measures compound symptom-medication score (cSMS) are relieved by intralymphatic immunotherapy (ILIT). The participants are asked for a three-year period to attend annual consultations and to daily fill in an online questionnaire about their allergy symptoms and medication use during the grass pollen season (100 days).
High attrition rates have been a problem in previous ILIT trials. High attrition affects generalizability, validity and reliability of a trial. To increase retention and reporting in the ILIT.NU trial, a motivation-enhancing web-based app has been developed. The web app is based on the Self-Determination Theory and is developed in collaboration with patient partners and clinicians. Participants are randomized across treatment group to either the motivation-enhancing web app or the standard reporting method. The project is conducted as a Study Within a Trial (SWAT).
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
- Participants enrolled in the ILIT.NU trial
Exclusion criteria
- Participants not enrolled in the ILIT.NU trial, Denmark
Trial design
Primary purpose
Allocation
Interventional model
Masking
224 participants in 2 patient groups
Trial contacts and locations
Loading...
Central trial contact
Jan Elo Jørgensen, PhD; Hans Jürgen Hoffmann, PhD
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal